Abstract
AbstractCritical Path Institute (C‐Path) is a nonprofit organization that brings together patient groups, academic institutions, the pharmaceutical industry and regulatory agencies from around the world to improve public health. C‐Path provides the legal, scientific, and regulatory infrastructure to generate a unique neutral environment for medical product development, supported by more than a decade of experience in data standards development, platform development and hosting, patient‐level data privacy stewardship, data platform security, and controlled access methodology. The Critical Path for Alzheimer’s Disease (CPAD) is a pre‐competitive consortium that aims to promote, support, and manage a diverse source and format of data and facilitate knowledge sharing from the Alzheimer disease (AD) drug development community. The CPAD database currently contains 65 clinical trials and observational studies, with over 93,000 individual anonymized patient‐level records, with global access to many datasets through the C‐Path Online Data Repository (CODR). The unparalleled breadth, depth and wealth of data will enable us to discover yet‐to‐be identified unmet needs and unanswered questions. Further, CODR is interoperable with the Global Alzheimer’s Association Interactive Network (GAAIN), Vivli and other data platforms. The secure and neutral data sharing framework of CPAD has resulted in the development of several regulatory‐grade tools that help optimize drug development and accelerate bringing new therapies to patients in need. Sufficient case examples of successful data sharing are now available and should inform and encourage future data sharing initiatives.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.